http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2257224-C1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16 |
| filingDate | 2004-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2005-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa840d9d673d601be6281ec095cdec22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2898f39bec00d2217c5d9c86d0644619 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa90b8cb2d8aee75000427878ff61e9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_031c6608f7baef37b2de1c708aa1ba0c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f088dd228795ca3f4dab67f949c35df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0b2878a01fde93ac4447a5e5330b4f1 |
| publicationDate | 2005-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2257224-C1 |
| titleOfInvention | Method for preparing human plasmin concentrate and product for its using in medicine |
| abstract | FIELD: medicine, biotechnology, pharmaceutical industry, veterinary science. n SUBSTANCE: method involves addition of tris-HCl buffer (pH 7.5) containing 0.1 M of lysine and 5 mM of EDTA to the Cohn's fraction followed by incubation and centrifugation. Prepared suspension is incubated with 10% PEG-3000 and after centrifugation the solution is applied onto column with lysine-Sepharose at pH 7.5 and plasminogen is eluted with buffer solution at pH 3.5 containing 0.1 M of glycine, 30 mM of lysine and 5 mM of caprylic acid. Then plasminogen is incubated with streptokinase in tris-buffer (pH 7.5) containing 15 mM of lysine, 10 mM of ε-aminocaproic acid and 50% of glycerol. Then method involves chromatography on column with benzamidine-Sepharose at pH 8.5 and elution with buffer at pH 3.5 containing 0.1 M of glycine, 30 mM of lysine, and the end product is lyophilized that comprises about 30 IU/ml of plasmin with purity above 98%, at least 10 mM of lysine and 10 mM of glycine in an aqueous solution at pH about 3.5. The prepared product shows apyrogenic property, absence of toxicity in experiments in laboratory animals and it doesn't cause allergic or other adverse response reactions in intracutaneous or intravenous administrations, and the preparation doesn't cause defects in the vision field after its an intraorbital route of administration. n EFFECT: improved preparing method, valuable medicinal properties of plasmin. n 7 cl, 1 ex |
| priorityDate | 2004-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 119.